AVIR
NASDAQAtea Pharmaceuticals Inc.
News · 26 weeks30+75%
2025-12-072026-05-31
Mix1790d
- SEC Filings6(35%)
- Other4(24%)
- Earnings3(18%)
- Insider3(18%)
- Offering1(6%)
Latest news
25 items- PRAtea Pharmaceuticals Presents New Drug-Drug Interaction Results Supporting Potential Best-in-Class Profile of the Regimen of Bemnifosbuvir and Ruzasvir for the Treatment of Hepatitis C Virus at EASL Congress 2026BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced Phase 1 results which further demonstrate that the fixed-dose combination regimen of bemnifosbuvir and ruzasvir (BEM/RZR) for the treatment of hepatitis C virus (HCV) has a low risk of drug-drug interaction. These results support the use of BEM/RZR with commonly used medications, including the proton pump inhibitor (PPI) omeprazole and the cholesterol-lowering drug rosuvastatin. The Company is also presenting data demonstrating h
- INSIDERAmendment: Director Murphy Polly A. bought $25,446 worth of shares (6,100 units at $4.17), increasing direct ownership by 7% to 92,145 units (SEC Form 4)4/A - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- INSIDERDirector Murphy Polly A. bought $25,446 worth of shares (6,100 units at $4.17), increasing direct ownership by 7% to 92,145 units (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- PRAtea Pharmaceuticals to Present Three Abstracts at EASL 2026 Congress Highlighting Progress Across Viral Hepatitis PipelineBOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that three abstracts have been accepted for presentation at the European Association for the Study of the Liver (EASL) Congress 2026, taking place May 27-30th in Barcelona, Spain. The presentations include two posters supporting Atea's fixed-dose combination regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, for the treatment of hepatitis C virus (HCV). Also being presented and d
- SECSEC Form 10-Q filed by Atea Pharmaceuticals Inc.10-Q - Atea Pharmaceuticals, Inc. (0001593899) (Filer)
- SECAtea Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Atea Pharmaceuticals, Inc. (0001593899) (Filer)
- PRAtea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business UpdateC-BEYOND Phase 3 North American Trial for Treatment of Hepatitis C Virus (HCV) Remains on Track with Topline Results Expected Mid-2026 C-FORWARD Phase 3 Trial Outside North America for Treatment of HCV on Track to Complete Enrollment Mid-2026; Topline Results Expected Around Year-End 2026 Encouraging Preclinical Data Support AT-587 as a Potential First-in-Class Therapy for Hepatitis E Virus (HEV); Phase 1 Initiation Expected Mid-2026 Company Holding Conference Call Today at 4:30 pm ET BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of ora
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Atea Pharmaceuticals Inc.SCHEDULE 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)
- PRAtea Pharmaceuticals to Host First Quarter 2026 Financial Results and Business Update Conference Call on May 12, 2026BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Tuesday, May 12, 2026, at 4:30 p.m. ET to report financial results for the first quarter ended March 31, 2026, and to provide a business update. To access the live conference call, participants may register here. The live audio webcast of the call will be available under "Events and Presentations" in the Investor Relations section of the Atea Pharmaceuticals website a
- SECSEC Form DEFA14A filed by Atea Pharmaceuticals Inc.DEFA14A - Atea Pharmaceuticals, Inc. (0001593899) (Filer)
- SECSEC Form DEF 14A filed by Atea Pharmaceuticals Inc.DEF 14A - Atea Pharmaceuticals, Inc. (0001593899) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Atea Pharmaceuticals Inc.SCHEDULE 13G/A - Atea Pharmaceuticals, Inc. (0001593899) (Subject)
- PRReAlta Life Sciences Appoints Howard Berman, Ph.D., as CEO and Kia Motesharei, Ph.D., as President and COOAdditions Bring Extensive Capital Markets and Business Transaction Expertise to Company as it Advances Pegtarazimod into Late-Stage Clinical Trials ReAlta Life Sciences Inc., a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to revolutionize the treatment of inflammatory disorders, today announced the appointments of Howard Berman, Ph.D., as Chairman and Chief Executive Officer and Kia Motesharei, Ph.D., as President and Chief Operating Officer. Dr. Berman, who has served as Executive Chairman since November 2025, will lead ReAlta's overall strategy, clinical development, and corporate execution, while Dr.
- INSIDEROfficer Corcoran Andrea exercised 60,000 shares at a strike of $1.24, increasing direct ownership by 8% to 823,576 units (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- SECSEC Form 10-K filed by Atea Pharmaceuticals Inc.10-K - Atea Pharmaceuticals, Inc. (0001593899) (Filer)
- SECAtea Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Atea Pharmaceuticals, Inc. (0001593899) (Filer)
- PRAtea Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateAdvanced Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV) in 2025 with Topline Results from North American C-BEYOND Trial Expected Mid-2026 and Topline Results from C-FORWARD Trial Outside North America Anticipated Year-End 2026 Presented Results Reinforcing Bemnifosbuvir/Ruzasvir as a Potential Best-in-Class Regimen for the Treatment of HCV at the 2025 EASL Congress and The Liver Meeting® 2025, the Annual Meeting of AASLD Physician KOLs Underscored the Need for a New Optimized HCV Regimen to Address Treatment Paradigm Shifts, Including Test-and-Treat Model of Care Expanded Antiviral Pipeline with New Hepatitis E Virus (HEV) Program; Lead Product Candidate AT-587 Expected
- PRAtea Pharmaceuticals to Host Fourth Quarter and Full Year 2025 Financial Results and Business Update Conference Call on March 5, 2026BOSTON, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced that it will host a live conference call and audio webcast on Thursday, March 5, 2026, at 4:30 p.m. ET to report financial results for the fourth quarter and full year ended December 31, 2025, and to provide a business update. To access the live conference call, participants may register here. The live audio webcast of the call will be available under "Events and Presentations" in the Investor Relations section of the Atea Phar
- PRAtea Pharmaceuticals Presents Preclinical Results Supporting First-in-Class Potential of AT-587 for Treatment of Hepatitis E Virus at CROI 2026Results Demonstrate AT-587 To Be Highly Potent In Vitro Against Hepatitis E Virus Initiation of Phase 1 Clinical Program Anticipated Mid-2026 BOSTON, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a late-stage clinical biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced in vitro results showing that two proprietary oral nucleotide analogs, AT-587 and AT-2490, exhibit promising antiviral profiles as potential first-in-class inhibitors for the treatment of Hepatitis E virus (HEV) infection, a positive-sense, single-stranded RNA virus that primarily infec
- SECSEC Form SCHEDULE 13G filed by Atea Pharmaceuticals Inc.SCHEDULE 13G - Atea Pharmaceuticals, Inc. (0001593899) (Subject)
- INSIDERChief Medical Officer Horga Maria Arantxa converted options into 51,283 shares and covered exercise/tax liability with 16,073 shares, increasing direct ownership by 58% to 96,086 units (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- INSIDERChief Commercial Officer Vavricka John converted options into 42,083 shares and covered exercise/tax liability with 11,570 shares, increasing direct ownership by 59% to 82,594 units (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- INSIDERChief Development Officer Hammond Janet Mj converted options into 58,050 shares and covered exercise/tax liability with 14,136 shares, increasing direct ownership by 52% to 127,665 units (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- INSIDEROfficer Corcoran Andrea converted options into 54,866 shares and covered exercise/tax liability with 16,104 shares, increasing direct ownership by 5% to 763,576 units (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
- INSIDERPresident, CEO, and Chairman Sommadossi Jean-Pierre covered exercise/tax liability with 106,093 shares and exercised 572,983 shares at a strike of $0.65, increasing direct ownership by 155% to 767,830 units (SEC Form 4)4 - Atea Pharmaceuticals, Inc. (0001593899) (Issuer)
AVIR FAQ
7 questionsWhat does Atea Pharmaceuticals Inc. do?
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, a novel antiviral agent that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 that is in...Where does AVIR stock trade?
Atea Pharmaceuticals Inc. (AVIR) is listed on NASDAQ.What sector and industry is AVIR in?
Atea Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Atea Pharmaceuticals Inc. go public?
Atea Pharmaceuticals Inc. (AVIR) completed its IPO in 2020.What are analysts saying about AVIR?
Atea Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Morgan Stanley: Equal-Weight with a $688.00 price target on 2024-08-13. Recent price targets range from $688.00 to $1100.00.What companies are similar to AVIR?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare AVIR side-by-side with any of them on Quantisnow.How can I track AVIR on Quantisnow?
Quantisnow aggregates Atea Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AVIR to receive live email and push alerts on every new disclosure.